drug

asfotase alfa

Marketedupdated 5mo ago

by Alexion Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying asfotase alfa

phase3Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfaactive not recruitingn=43
—A Prospective Sub-Study of the Global Hypophosphatasia Registryrecruitingn=30
—Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)completedn=50

News(2)

BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.
fiercebiotech · 1mo ago
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
biopharma_dive · 3mo ago

Data sources

ClinicalTrials.gov

last refreshed 3h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

asfotase alfa

Marketedupdated 5mo ago

by Alexion Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying asfotase alfa

phase3Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfaactive not recruitingn=43
—A Prospective Sub-Study of the Global Hypophosphatasia Registryrecruitingn=30
—Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)completedn=50

News(2)

BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.
fiercebiotech · 1mo ago
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
biopharma_dive · 3mo ago

Data sources

ClinicalTrials.gov

last refreshed 3h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

asfotase alfa

all catalysts(0)

Trials studying asfotase alfa

News(2)

Report a data issue

comments(0)

asfotase alfa

all catalysts(0)

Trials studying asfotase alfa

News(2)

Report a data issue

comments(0)